

Akmal Ahmed Safwat  
Clinical Associate Professor  
Department of Clinical Medicine - DCPT - Danish Center for Particle Therapy  
**Type of address: Postal address.**  
Palle Juul-Jensens Boulevard 99  
8200  
Aarhus N  
Denmark  
**Email:** akmal@clin.au.dk  
**Mobile:** +4529781229  
**Phone:** +4578464420

## Year of birth

1961

## Educations

2005 Specialist Clinical Oncology, Denmark  
1995 Specialist Radiation Oncology, Egypt  
1977-1983 College of Medicine, Cairo University, Egypt

## Academic degrees

1995 Medical  
1988 Master of Science in Radiation Therapy and Oncology

## Research areas

Sarcoma clinical studies  
Mesenchymal Cancer Stem Cells chemo- and radio-sensitivity  
Radiobiological and immunological aspects of whole body irradiation

## Present position

2007- Consultant and Lector of Clinical Oncology, Department of Oncology, Aarhus University Hospital, Denmark

## Previous positions

2005-2007 Specialist, Clinical Oncology, Oncology Department, Aarhus University Hospital, Denmark  
2002 Postdoc, Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark

## Publications and presentations

Publications: ?, Peer-reviewed articles: 33, Book chapters: 2, H-index: 16, Citations: 77, Patents: ?, Scientific meeting presentations (oral): 40.

## Board memberships

Danish Sarcoma Group

## Organization of clinical trials

INITIATOR AND PRINCIPLE INVESTIGATOR:

A phase II study of the use of low-dose total body irradiation as an adjuvant therapy for patients with high-risk NHL intermediate grade. (Ended and results published)

A phase II study using low-dose total body irradiation and IL-2 in treatment of metastatic malignant melanoma, Aarhus Universitetshospital, Denmark. (Ended and results published)

A phase II study of the use of low-dose total body irradiation as an adjuvant therapy for elderly patients with high-risk diffuse B-cell NHL. (Ended and results pending)

NATIONAL COORDINATOR:

EORTC phase II study on the use of preoperative radiotherapy in treatment of retroperitoneal sarcoma (ongoing)

## Supervision

4 Undergraduate thesis, Aarhus University (2007-2013)  
4 PhD. thesis (3 ongoing), Aarhus University Hospital (2002-2007)  
3 PhD. thesis, Cairo University (1996-2002)

## Awards and grants

UICC "ICRETT" scholarship, to :  
Department of Medical Physics, Essen, Germany (Juli-August 1990)  
The ESTRO-VARIAN Clinical/Radiobiology Research Award (1995)  
UICC Yamagiwa-Yoshida Cancer Research Study Grant (1999)  
A Danish Medical Research Council post-doctoral fellowship (January-December 2001)  
William Nielsen honorary prise (2010)

## Major research grants

The Danish Cancer Society (2001 & 2002)  
The Danish Medical Research Council (2001)  
King Christian the 10th Fund (2001)  
A-P Møller and wife Fund (2001)  
Preben and Anna Simonsen fund (2001)  
The radiumstationen Research Fund (2001)  
Direktør Leo Nielsen og hustrus Legat (2001)  
Frits, Georg og Marie Cecilie Gluds Legat (2001)  
Max og Inge Wørzners Mindelegat (2001)  
The Danish Medical Research Council (2005)  
Novo-Nordisk Fund (2005)  
Agnes and Poul Friis Fund (2005)  
Radiumstationen forskningsfond (2007)

## Memberships

European Society for Therapeutic Radiology and Oncology (ESTRO)  
Danish Sarcoma Group (DSG)  
Danish Society for Clinical Oncology (DSKO)  
Connective Tissue Oncology Society (CTOS)  
International Pædiatric Radiation Oncology Society (PROS)

## Publications

### **Comprehensive radiotherapy for pediatric Ewing Sarcoma: Outcomes of a prospective proton study**

Bronk, J. K., McAleer, M. F., McGovern, S. L., Lassen-Ramshad, Y., Safwat, A., Daw, N. C., Rainusso, N., Mahajan, A., Grosshans, D. R. & Paulino, A. C., Jun 2024, In: Radiotherapy and Oncology. 195, 110270.

### **Doxorubicin concentrations in bone tumour-relevant tissues after bolus and continuous infusion: a randomized porcine microdialysis study**

Jørgensen, A. R., Bue, M., Hanberg, P., Petersen, E. K., Harlev, C., Hansen, J., Baad-Hansen, T., Safwat, A. & Stilling, M., Jun 2024, In: Cancer Chemotherapy and Pharmacology. 93, 6, p. 555-564 10 p.

### **Management of the vertebrae as an organ at risk in paediatric radiotherapy clinical trials: Initial QUARTET experience**

Turcas, A., Kelly, S. M., Bernier-Chastagner, V., Bolle, S., Cameron, A., Corning, C., Clementel, E., Dieckmann, K., Davila Fajardo, R., Gaze, M. N., Laprie, A., Magelssen, H., Meroni, S., Pignoli, E., Safwat, A., Scarzello, G., Talbot, J., Timmermann, B., Boterberg, T. & Mandeville, H. C., Oct 2023, In: Radiotherapy and Oncology. 187, 109810.

### **Intra-abdominal desmoplastic small round cell tumor: The European pediatric Soft tissue sarcoma Study Group (EpSSG) experience**

Berlanga, P., Orbach, D., Schoot, R. A., Casanova, M., Alaggio, R., Corradini, N., Brennan, B., Ramirez-Villar, G. L., Hjalgrim, L. L., Chisholm, J. C., Bisogno, G., Coppadoro, B., Safwat, A., Merks, J. H. M., Burrieza, G. G., van Noesel, M. M. & Ferrari, A., Sept 2023, In: Pediatric Blood and Cancer. 70, 9, 9 p., e30447.

### **Metastatic adult-type non-rhabdomyosarcoma soft tissue sarcomas in children and adolescents: A cohort study from the European paediatric Soft tissue sarcoma Study Group**

Ferrari, A., Orbach, D., Casanova, M., van Noesel, M. M., Berlanga, P., Brennan, B., Corradini, N., Schoot, R. A., Ramirez-Villar, G. L., Hjalgrim, L. L., Alaggio, R., Guillen Burrieza, G., Safwat, A., Cameron, A. L., van Rijn, R. R., Minard-

Colin, V., Zanetti, I., Bisogno, G., Chisholm, J. C. & Merks, J. H. M., Aug 2023, In: Cancer. 129, 16, p. 2542-2552 11 p.

**Giant cell tumour of bone in os sacrum of a prepubertal girl – Surgical and medical treatment with zoledronate and denosumab**

Beck-Nielsen, S. S., Hasle, H., Safwat, A., Valancius, K., Langdahl, B. & Hansen, E. S., Jun 2023, In: Bone Reports. 18, 7 p., 101687.

**Multidrug resistance protein 1 silencing in osteosarcoma and chondrosarcoma cell lines**

Freund, S. S., Bendtsen, M. M., Safwat, A. & Joergensen, P. H., Apr 2023, In: Journal of Cancer Research and Therapeutics. 19, 8, p. S278-S284

**The significance of margins in pediatric Non-Rhabdomyosarcoma soft tissue sarcomas: Consensus on surgical margin definition harmonization from the INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT)**

Sparber-Sauer, M., Ferrari, A. C., Spunt, S., Vokuhl, C., Casey, D., Lautz, T., Meyer, W., Walterhouse, D., Pajtler, K., Alaggio, R., Schmidt, A., Safwat, A. A., Timmermann, B., Dall'igna, P., Chen, S., Weiss, A. & Orbach, D., Feb 2023, In: Cancer medicine. 12, 10, p. 11719-11730 12 p.

**Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour**

Georgiesh, T., Aggerholm-Pedersen, N., Schoffski, P., Zhang, Y., Napolitano, A., Bovee, J. V. M. G., Hjelle, A., Tang, G., Spalek, M., Nannini, M., Swanson, D., Baad-Hansen, T., Sciot, R., Hesla, A. C., Huang, P., Dorleijn, D., Haugland, H. K., Lacambra, M., Skoczylas, J., Pantaleo, M. A., & 13 others Haas, R. L., Meza-Zepeda, L. A., Haller, F., Czarnecka, A. M., Loong, H., Jebesen, N. L., van de Sande, M., Jones, R. L., Haglund, F., Timmermans, I., Safwat, A., Bjerkehagen, B. & Boye, K., Nov 2022, In: British Journal of Cancer. 127, 10, p. 1793–1798 6 p.

**Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments**

Chargari, C., Haie-Meder, C., Espenel, S., Garcia, M. A., Ben-Arush, M., Bolle, S., Borjesson, A., Cesen, M., Lago, R. C., Defachelles, A. S., De Moerloose, B., Devalck, C., Edslev, P., Farinha, N. J., Francotte, N., Glosli, H., Gouy, S., Burrieza, G. G., Helfre, S., Irtan, S., & 27 others Kattamis, A., Lacerda, A., Levy, A., Hjalgrim, L. L., Mansuy, L., Mascard, E., Moalla, S., Orbach, D., Owens, C., Philippe-Chomette, P., Pizer, B., Pluchart, C., Renard, M., Roghien, A. G. W., Rome, A., Sarnacki, S., Safwat, A., Schiavetti, A., Serre, J., Verite, C., Weid, N. V. D., Wysocki, M., Valteay-Couanet, D., Deutsch, E., Minard-Colin, V., Martelli, H. & Guérin, F., Jul 2022, In: International Journal of Radiation Oncology Biology Physics. 113, 3, p. 602-613 12 p.

**Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up**

ESMO Guidelines Committee, EURACAN and GENTURIS, Jan 2022, In: Annals of Oncology. 33, 1, p. 20-33 14 p.

**Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up**

Strauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Boye, K., Brennan, B., Brodowicz, T., Buonadonna, A., de Álava, E., Dei Tos, A. P., Garcia Del Muro, X., Dufresne, A., & 47 others Eriksson, M., Fagioli, F., Fedenko, A., Ferraresi, V., Ferrari, A., Gaspar, N., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Gronchi, A., Haas, R., Hassan, A. B., Hecker-Nolting, S., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R. L., Jungels, C., Jutte, P., Kager, L., Kasper, B., Kawai, A., Kopeckova, K., Krákorová, D. A., Le Cesne, A., Le Grange, F., Legius, E., Leithner, A., Safwat, A. A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schöffski, P., Sleijfer, S., Strauss, D., Sundby Hall, K., Trama, A., Unk, M., van de Sande, M. A. J., van der Graaf, W. T. A., Van Houdt, W., Frebourg, T., Ladenstein, R., Casali, P. G., Stacchiotti, S. & ESMO Guidelines Committee, EURACAN, GENTURIS and ERN PaedCan. Electronic address: clinicalguidelines@esmo.org, Dec 2021, In: Annals of oncology : official journal of the European Society for Medical Oncology. 32, 12, p. 1520-1536 17 p.

**European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN**

Blay, J. Y., Casali, P., Bouvier, C., Dehais, C., Galloway, I., Gietema, J., Halámková, J., Hindi, N., Idbaih, A., Kinloch, E., Klümpen, H. J., Kolarova, T., Kopeckova, K., Lovey, J., Magalhaes, M., Oselin, K., Piperno-Neumann, S., Ravnsbaek, A., Rogasik, M., Safwat, A., & 8 others Scheipl, S., Seckl, M., Taylor, J., Temnyk, M., Trama, A., Urbonas, M., Wartenberg, M. & Weinman, A., Aug 2021, In: ESMO Open. 6, 4, 10 p., 100174.

**Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG)**

Ferrari, A., van Noesel, M. M., Brennan, B., Zanetti, I., Corradini, N., Casanova, M., Berlanga, P., Merks, J. H. M., Alaggio, R., Schifflers, S., Ramirez-Villar, G. L., Giraudo, C., Burrieza, G. G., Safwat, A., Bisogno, G., De Salvo, G. L. & Orbach, D., Aug 2021, In: *The Lancet Child & Adolescent Health*. 5, 8, p. 546-558 13 p.

**Non-rhabdomyosarcoma soft-tissue sarcoma**

Milgrom, S. A., Million, L., Mandeville, H., Safwat, A., Ermoian, R. P. & Terezakis, S., May 2021, In: *Pediatric Blood and Cancer*. 68, S2, 8 p., e28279.

**Radiation-Induced Sarcoma: A Retrospective Population-Based Study Over 34 Years in a Single Institution**

Callesen, L. B., Safwat, A., Rose, H. K., Sørensen, F. B., Baad-Hansen, T. & Aggerholm-Pedersen, N., May 2021, In: *Clinical Oncology*. 33, 5, p. e232-e238

**Rhabdomyosarcoma in Adults: A Retrospective Analysis of Case Records Diagnosed between 1979 and 2018 in Western Denmark**

Mäkinen, V-N., Safwat, A. & Aggerholm-Pedersen, N., 2021, In: *Sarcoma*. 2021, p. 9948885

**The Feasibility of Implementing Deep Inspiration Breath-Hold for Pediatric Radiation Therapy**

Lundgaard, A. Y., Josipovic, M., Rechner, L. A., Bidstrup, P. E., Hansen, R., Damkjaer, S. S., Joergensen, M., Safwat, A., Specht, L., Hjalgrim, L. L. & Maraldo, M. V., Apr 2020, In: *International Journal of Radiation Oncology Biology Physics*. 106, 5, p. 977-984 8 p.

**The association between socioeconomic position and tumour size, grade, stage, and mortality in Danish sarcoma patients - A national, observational study from 2000 to 2013**

Raedkjaer, M., Maretty-Kongstad, K., Baad-Hansen, T., Safwat, A., Petersen, M. M., Keller, J. & Vedsted, P., Feb 2020, In: *Acta Oncologica*. 59, 2, p. 127-133 7 p.

**Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience**

Aggerholm-Pedersen, N., Rossen, P., Rose, H. & Safwat, A., 2020, In: *Translational Oncology*. 13, 2, p. 295-299 5 p.

**Use of Healthcare Services Two Years before Diagnosis in Danish Sarcoma Patients, 2000-2013**

Rædkjær, M., Maretty-Kongstad, K., Baad-Hansen, T., Safwat, A., Petersen, M. M., Keller, J. & Vedsted, P., May 2019, In: *Sarcoma*. 2019, 8108590.

**The prognostic role of inflammation-scores on overall survival in lung cancer patients**

Paulsen, B. S., Meldgaard, P., Sørensen, B. S., Safwat, A. A. & Aggerholm-Pedersen, N., Mar 2019, In: *Acta Oncologica*. 58, 3, p. 371-376 6 p.

**Chondrosarcoma: the impact of comorbidity - 30 years of experience from a population-based database including 199 consecutive chondrosarcoma patients**

Aggerholm-Pedersen, N., Maretty-Nielsen, K., Baerentzen, S., Jorgensen, P. H., Hansen, B. H., Baad-Hansen, T., Keller, J. & Safwat, A., 2019, In: *Orthopedic research and reviews*. 11, p. 109-116 8 p.

**Serum Biomarkers as Prognostic Factors for Metastatic Sarcoma**

Aggerholm-Pedersen, N., Maretty-Kongstad, K., Keller, J. Ø. & Safwat, A., 2019, In: *Clinical Oncology*. 31, 4, p. 242-249 8 p.

**Soft Tissue Sarcomas of the Thoracic Wall: More Prone to Higher Mortality, and Local RecurrenceA Single Institution Long-Term Follow-up Study**

Soerensen, T. R., Raedkjaer, M., Jorgensen, P. H., Hoejsgaard, A., Safwat, A. & Baad-Hansen, T., 2019, In: *International Journal of Surgical Oncology*. 2019, 7 p., 2350157.

**Solitary Fibrous Tumour: A Single Institution Retrospective Study and Further Validation of a Prognostic Risk Assessment System**

Friis, R. B., Safwat, A., Baad-Hansen, T. & Aggerholm-Pedersen, N., Dec 2018, In: *Clinical Oncology*. 30, 12, p. 798-804 7 p.

**Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up**  
ESMO Guidelines Committee, PaedCan and ERN EURACAN, 1 Oct 2018, In: *Annals of Oncology*. 29, Supplement\_4, p. iv79-iv95 17 p.

**Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up**  
Robinson, M. H., Rutkowski, P., Schöffski, P., Sleijfer, S., Stacchiotti, S., Sundby Hall, K., Unk, M., Van Coevorden, F., Van der Graaf, W., Whelan, J., Wardelmann, E., Zaikova, O., Blay, J. Y. & ESMO Guidelines Committee and EURACAN, 1 Oct 2018, In: *Annals of Oncology*. 29, Supplement\_4, p. iv68-iv78 11 p.

**Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up**  
ESMO Guidelines Committee and EURACAN, 1 Oct 2018, In: *Annals of Oncology*. 29, Supplement\_4, p. 268-269 2 p.

**The impact of comorbidity on mortality in Danish sarcoma patients from 2000-2013: A nationwide population-based multicentre study**

Raedkjaer, M., Maretty-Kongstad, K., Baad-Hansen, T., Jørgensen, P. H., Safwat, A., Vedsted, P., Petersen, M. M., Hovgaard, T., Nymark, T. & Keller, J., 1 Jun 2018, In: *PLOS ONE*. 13, 6, 13 p., e0198933.

**TEDDI: radiotherapy delivery in deep inspiration for pediatric patients - a NOPHO feasibility study**

Lundgaard, A. Y., Hjalgrim, L. L., Rechner, L. A., Josipovic, M., Joergensen, M., Aznar, M. C., Berthelsen, A. K., Borgwardt, L., Johansen, C., Loft, A., Safwat, A., Vaalavirta, L., Specht, L. & Maraldo, M. V., 27 Mar 2018, In: *Radiation Oncology*. 13, 1, 6 p., 56.

**A Validated Prognostic Biomarker Score for Adult Patients with Nonmetastatic Soft Tissue Sarcomas of the Trunk and Extremities**

Maretty-Kongstad, K., Aggerholm-Pedersen, N., Keller, J. & Safwat, A., Dec 2017, In: *Translational Oncology*. 10, 6, p. 942-948 7 p.

**Factors associated with reduced functional outcome and quality of life in patients having limb-sparing surgery for soft tissue sarcomas - a national multicenter study of 128 patients**

Saebye, C., Fugloe, H. M., Nymark, T., Safwat, A., Petersen, M. M., Baad-Hansen, T., Krarup-Hansen, A. & Keller, J., Feb 2017, In: *Acta Oncologica*. 56, 2, p. 239-244 6 p.

**Imaging investigations before referral to a sarcoma center delay the final diagnosis of musculoskeletal sarcoma**

Buvarp Dyrop, H., Vedsted, P., Rædkjær, M., Safwat, A. & Keller, J., 12 Jan 2017, In: *Acta Orthopaedica*. 88, 2, p. 211-216 6 p.

**Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis**

Kollar, A., Jones, R. L., Stacchiotti, S., Gelderblom, H., Guida, M., Grignani, G., Steeghs, N., Safwat, A., Katz, D., Duffaud, F., Sleijfer, S., van der Graaf, W. T., Touati, N., Litiere, S., Marreaud, S., Gronchi, A. & Kasper, B., 2017, In: *Acta Oncologica*. 56, 1, p. 88-92 5 p.

**A prognostic profile of hypoxia-induced genes for localised high-grade soft tissue sarcoma**

Aggerholm-Pedersen, N., Sørensen, B. S., Overgaard, J., Toustrup, K., Bærentzen, S., Nielsen, O. S., Maretty-Kongstad, K., Nordmark, M., Alsner, J. & Safwat, A., 25 Oct 2016, In: *B J C*. 115, 9, p. 1096-1104 9 p.

**Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOSan open-label, international, randomised controlled trial-1): an open-label, international, randomised controlled trial**

Marina, N. M., Smeland, S., Bielack, S. S., Bernstein, M., Jovic, G., Krailo, M. D., Hook, J. M., Arndt, C., van den Berg, H., Brennan, B., Brichard, B., Brown, K. L. B., Butterfass-Bahloul, T., Calaminus, G., Daldrup-Link, H. E., Eriksson, M., Gebhardt, M. C., Gelderblom, H., Gerss, J., Goldsby, R., & 33 othersGoorin, A., Gorlick, R., Grier, H. E., Hale, J. P., Hall, K. S., Harges, J., Hawkins, D. S., Helmke, K., Hogendoorn, P. C. W., Isakoff, M. S., Janeway, K. A., Jürgens, H., Kager, L., Kühne, T., Lau, C. C., Leavey, P. J., Lessnick, S. L., Mascarenhas, L., Meyers, P. A., Mottl, H., Nathrath, M., Papai, Z., Randall, R. L., Reichardt, P., Renard, M., Safwat, A. A., Schwartz, C. L., Stevens, M. C. G., Strauss, S. J., Teot, L.,

Werner, M., Sydes, M. R. & Whelan, J. S., Oct 2016, In: The Lancet Oncology. 17, 10, p. 1396-1408 13 p.

**The Prognostic Value of Serum Biomarkers in Localized Bone Sarcoma**

Aggerholm-Pedersen, N., Maretty-Kongstad, K., Keller, J., Baerentzen, S. & Safwat, A., Aug 2016, In: Translational Oncology. 9, 4, p. 322-8 7 p.

**A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas**

Vitfell-Rasmussen, J., Judson, I., Safwat, A., Jones, R. L., Rossen, P. B., Lind-Hansen, M., Knoblauch, P. & Krarup-Hansen, A., 14 Jun 2016, In: Sarcoma. 2016, 8 p., 2090271.

**Primary breast sarcoma: A retrospective study over 35 years from a single institution**

Holm, M., Aggerholm-Pedersen, N., Mele, M., Jørgensen, P., Baerentzen, S. & Safwat, A., 3 May 2016, In: Acta Oncologica. 55, 5, p. 584-590 7 p.

**Primary breast sarcoma: A retrospective study over 35 years from a single institution**

Holm, M. P., Aggerholm-Pedersen, N., Mele, M., Jørgensen, P. H., Baerentzen, S. & Safwat, A., May 2016, In: Acta Oncologica. 55, 5, p. 584-90 7 p.

**Characteristics of 64 sarcoma patients referred to a sarcoma center after unplanned excision**

Dyrop, H. B., Safwat, A., Vedsted, P., Nielsen, K. M., Hansen, B. H., Jørgensen, P. H., Baad-Hansen, T. & Keller, J., Feb 2016, In: Journal of Surgical Oncology. 113, 2, p. 235-9 5 p.

**Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy**

Aggerholm-Pedersen, N., Demuth, C., Safwat, A., Meldgaard, P., Kassem, M. & Sandahl Sorensen, B., 2016, In: Stem Cells and Development. 2016, p. 9601493 9601493.

**Routes to Diagnosis for Suspected Sarcoma: The Impact of Symptoms and Clinical Findings on the Diagnostic Process**

Buvarp Dyrop, H., Vedsted, P., Rædkjær, M., Safwat, A. & Keller, J., 2016, In: Sarcoma. 2016, p. 8639272 8639272.

**Unsustained response to brentuximab as single agent therapy in a patient with CD30 positive angiosarcoma**

Holm, M. P., Hjorthaug, K., Bærentzen, S. & Safwat, A. A., 2016, In: Acta Oncologica. 55, 2, p. 251-253 3 p.

**The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia**

Schack, L. M. H., Mouritsen, L. S., Mouritsen, L. S., Krarup-Hansen, A. & Safwat, A. A., Jan 2015, In: Acta Oncologica. 54, 1, p. 34-40 7 p.

**Hypercalcemia in metastatic GIST caused by systemic elevated calcitriol: a case report and review of the literature**

Hygum, K., Wulff, C. N., Harsløf, T., Boysen, A. K., Rossen, P. B., Langdahl, B. L. & Safwat, A. A., 2015, In: B M C Cancer. 15, 5 p., 788.

**Alarm symptoms of soft-tissue and bone sarcoma in patients referred to a specialist center**

Dyrop, H. B., Vedsted, P., Safwat, A., Maretty-Nielsen, K., Hansen, B. H., Jørgensen, P. H., Baad-Hansen, T. & Keller, J., Dec 2014, In: Acta Orthopaedica. 85, 6, p. 657-662 6 p.

**The importance of reference gene analysis of formalin-fixed, paraffin-embedded samples from sarcoma patients - an often underestimated problem**

Aggerholm-Pedersen, N., Safwat, A. A., Bærentzen, S., Nordmark, M., Nielsen, O. S., Alsner, J. & Sørensen, B. S., Dec 2014, In: Translational Oncology. 7, 6, p. 687-93 7 p.

**Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients**

Safwat, A. A., Boysen, A., Lücke, A. & Rossen, P., Oct 2014, In: Acta Oncologica. 53, 10, p. 1451-4 4 p.

**Prevalence and prognostic impact of comorbidity in soft tissue sarcoma: A population-based cohort study**

Maretty-Nielsen, K., Aggerholm-Pedersen, N., Safwat, A., Baerentzen, S., Pedersen, A. B. & Keller, J., Sept 2014, In: Acta Oncologica. 53, 9, p. 1188-96 9 p.

**The importance of standardized treatment in high-grade osteosarcoma: 30 years of experience from a hospital-based database**

Aggerholm-Pedersen, N., Nielsen, K. M., Keller, J., Baerentzen, S., Schrøder, H., Jørgensen, P. H., Hansen, B. H., Nielsen, O. S. & Safwat, A., 24 Jun 2014, In: Acta Oncologica. p. 1-8 8 p.

**Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall: a cohort study of 922 consecutive patients**

Marett-Nielsen, K., Aggerholm-Pedersen, N., Safwat, A. A., Jørgensen, P. H., Hansen, B. H., Baerentzen, S., Pedersen, A. B. & Keller, J., Jun 2014, In: Acta Orthopaedica. 85, 3, p. 323-32 10 p.

**Validation of a Danish version of the Toronto Extremity Salvage Score questionnaire for patients with sarcoma in the extremities**

Saebye, C., Safwat, A., Kaa, A. K., Pedersen, N. A. & Keller, J., Jan 2014, In: Danish Medical Journal. 61, 1, 4 p., A4734.

**Comorbidity in adult bone sarcoma patients: a population-based cohort study**

Aggerholm-Pedersen, N., Marett-Nielsen, K., Keller, J., Bærentzen, S. & Safwat, A., 2014, In: Sarcoma. 2014, 9 p., 690316.

**Relative mortality in soft tissue sarcoma patients: a Danish population-based cohort study**

Marett-Nielsen, K., Aggerholm-Pedersen, N., Keller, J. Ø., Safwat, A. A., Baerentzen, S. & Pedersen, A. B., 2014, In: B M C Cancer. 14, 11 p., 682.

**Cancer Patient Pathways shortens waiting times and accelerates the diagnostic process of suspected sarcoma patients in Denmark**

Dyrop, H. B., Safwat, A., Vedsted, P., Marett-Nielsen, K., Hansen, B. H., Jørgensen, P. H., Baad-Hansen, T., Bünger, C. & Keller, J., Nov 2013, In: Health Policy. 113, 1-2, p. 110-7 8 p.

**Metastatic pattern, local relapse, and survival of patients with myxoid liposarcoma: a retrospective study of 45 patients**

Fuglø, H. M., Nielsen, K. M., Hovgaard, D., Keller, J. Ø., Safwat, A. A. & Petersen, M. M., 20 Jun 2013, In: Sarcoma. 2013, 6 p., 548628.

**Population-based Aarhus Sarcoma Registry: validity, completeness of registration, and incidence of bone and soft tissue sarcomas in western Denmark**

Nielsen, K. M., Aggerholm-Pedersen, N., Keller, J., Safwat, A., Baerentzen, S. & Pedersen, A. B., 6 Mar 2013, In: Clinical epidemiology. 5, 1, p. 45-56 12 p.

**Low-Grade Fibromyxoid Sarcoma: Incidence, Treatment Strategy of Metastases, and Clinical Significance of the FUS Gene**

Nielsen, K. M., Baerentzen, S., Keller, J., Dyrop, H. B. & Safwat, A., 2013, In: Sarcoma. 2013, 6 p., 256280.

**Tumour microenvironment and radiation response in sarcomas originating from tumourigenic human mesenchymal stem cells**

D'Andrea, F. P., Safwat, A. A., Burns, J. S., Kassem, M., Horsman, M. R. & Overgaard, J., Jun 2012, In: International Journal of Radiation Biology. 88, 6, p. 457-465 9 p.

**Sarcomas as a mise en abyme of mesenchymal stem cells: exploiting interrelationships for cell mediated anticancer therapy**

Burns, J. S., Safwat, A., Grisendi, G., Kassem, M. & Dominici, M., 2012, In: Cancer Letters. 325, 1, p. 1-10 10 p.

**Tumourigenicity and radiation resistance of mesenchymal stem cells**

D'Andrea, F. P., Horsman, M. R., Kassem, M., Overgaard, J. & Safwat, A. A., 2012, In: Acta Oncologica. 51, 5, p. 669-679 11 p.

**Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance**

D'Andrea, F. P., Safwat, A. A., Kassem, M., Gautier, L., Overgaard, J. & Horsman, M. R., Jun 2011, In: Radiotherapy & Oncology. 99, 3, p. 373-378 6 p.

**A Rare Case of CD30+, Radiation-Induced Cutaneous Angiosarcoma Misdiagnosed As T-Cell Lymphoma**

Aggerholm-Pedersen, N., Bærentzen, S., Jørgensen, P. H. & Safwat, A., 7 Feb 2011, In: Journal of Clinical Oncology.

**Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment**

Farr, K. P. & Safwat, A. A., 2011, In: Case Reports in Oncology. 4, 1, p. 229-35 7 p.

**Serum Sodium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution**

Aggerholm-Pedersen, N., Rasmussen, P., Dybdahl, H., Rossen, P., Nielsen, O. S. & Safwat, A., 2011, In: ISRN Oncology. 2011, p. 523915

**Serum sodium determines outcome of treatment of advanced GIST with Imatinib: a retrospective study of 80 patients from a single institution**

Pedersen, N., Rasmussen, P., Dybdahl, H., Rossen, P., Nielsen, O. S. & Safwat, A. A., 2011, In: ISRN Oncology. 1-7

**Final results of a phase II Danish trial testing low dose total body irradiation following Six bi-weekly RCHOP-14 plus 2 estra Rituximab in elderly high-risk patients with aggressive CD20+ diffuse large B-cell lymphoma (DLBCL)**

Safwat, A., Specht, L., Hansen, F., Hansen, M., Jurlander, J. & d'Amore, F. A., 2009, (Submitted) In: Cancer.

**Immunohistochemical estimates of angiogenesis, proliferative activity, p53 expression, and multiple drug resistance have no prognostic impact in osteosarcoma: A comparative clinicopathological investigation**

Sorensen, F. B., Jensen, K., Vaeth, M., Hager, H., Funder, A. M. D., Safwat, A., Keller, J. & Christensen, M., 2008, In: Sarcoma. 2008, 874075.

**Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation**

Sørensen, F. B., Jensen, K., Vaeth, M., Hager, H., Funder, A. M. D., Safwat, A., Keller, J. & Christensen, M., 2008, In: Sarcoma. 2008, p. 874075

**A phase II trial of low-dose total body irradiation and subcutaneous Interleukin-2 in metastatic melanoma**

Safwat, A., Schmidt, H., Bastholt, L., Fode, K., Larsen, S., Aggerholm, N. & Maase, H. V. D., 2005, In: Radiother. Oncol.. 77, 2, p. 143-147

**A randomized study of accelerated fractionation radiotherapy with and without mitomycin C in the treatment of locally advanced head and neck cancer**

Ezzat, M., Shouman, T., Zaza, K., Safwat, A., El-Khoudary, A., El-Senosi, M. & Ezzat, I., 2005, In: J Egypt Natl Cancer Inst. 17, 2, p. 85-92

**Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2**

Safwat, A. A., Aggerholm-Pedersen, N., Roitt, I., Overgaard, J. & Hokland, M., Jun 2004, In: European Journal of Cancer. 40, 9, p. 1412-1417 6 p.

**A phase II trial of adjuvant low-dose total body irradiation in non-Hodgkin's lymphoma patients following standard CHOP**

Safwat, A., Bayoumi, Y., Akkoush, H. & Mahmoud, H. K., 2004, In: Acta Oncologica. 43, p. 480-485 6 p.

**Low-dose total body irradiation augments the therapeutic effect of Interleukin-2 in a mouse model for metastatic malignant melanoma**

Safwat, A. A., Aggerholm, N., Roitt, I., Overgaard, J. & Hokland, M., Aug 2003, In: Journal of Experimental Therapeutics and Oncology. 3, 4, p. 161-168 8 p.



**The potential palliative role and possible immune modulatory effects of low-dose total body irradiation in relapsed or chemo-resistant non-Hodgkin's lymphoma**

Safwat, A. A., Bayoumy, Y., El-Sharkawy, N., Shaaban, K., Mansour, O. & Kamel, A., 2003, In: Radiotherapy & Oncology. 69, 1, p. 33-36 4 p.

**Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy**

Safwat, A. A., Bentzen, S. M., Turesson, I. & Hendry, J. H., 1 Jan 2002, In: International Journal of Radiation Oncology, Biology, Physics. 52, 1, p. 198-204 7 p.

**Time-course of the hazard of murine nephropathy induced by total-body irradiation**

Safwat, A., Bentzen, S., Nielsen, O. S. & Overgaard, J., 2000, In: International Journal of Radiation Biology. 76, 7, p. 979-83 5 p.

**A retrospective clinicopathological study of 37 patients with chordoma: A Danish national series.**

Safwat, A., Nielsen, O. S., Jurik, A. G., Keller, J. Ø., Weeth, E., Lund, B. & Jensen, O. M., 1997, In: Sarcoma. 1, 3-4, p. 161-165 5 p.

**Repair capacity of mouse lung after total body irradiation alone or combined with cyclophosphamide**

Safwat, A., Bentzen, S. M., Nielsen, O. S., Mahmoud, H. K. & Overgaard, J., Sept 1996, In: Radiotherapy & Oncology. 40, 3, p. 249-257 9 p.

**Effect of radiation dose rate and Cyclophosphamide on late pulmonary toxicity after total body radiation in a mouse model**

Safwat, A., Nielsen, O. S., El-Badawy, S. & Overgaard, J., Jan 1996, In: International Journal of Radiation Oncology, Biology, Physics. 34, 1, p. 85-91 7 p.

**Late renal damage after total body irradiation and bone marrow transplantation in a mouse model: effect of radiation fractionation**

Safwat, A. A., Nielsen, O. S., el-Badawy, S. & Overgaard, J., Jun 1995, In: European Journal of Cancer. 31A, 6, p. 987-992 6 p.

**Late renal damage after total body radiation and bone marrow transplantation in a mouse model: Effect of radiation fractionation**

Safwat, A., Nielsen, O. S., El-Badawy, S. & Overgaard, J., Jun 1995, In: European Journal of Cancer. 31A, 6, p. 987-992 6 p.

**Renal damage after total body irradiation in a mouse model for bone marrow transplantation: Effect of radiation dose rate**

Safwat, A., Nielsen, O. S., El-Bakky, H. A. & Overgaard, J., Mar 1995, In: Radiotherapy & Oncology. 34, 3, p. 203-209 7 p.

**The effect of sequence and time interval between cyclophosphamide and total body irradiation on lung and bone marrow damage following bone marrow transplantation in mice**

Nielsen, O. S., Safwat, A. & Overgaard, J., Oct 1993, In: Radiotherapy & Oncology. 29, 1, p. 51-59 9 p.

**Influence of time between total body irradiation and cyclophosphamide in bone marrow transplantation. A study on mice.**

Nielsen, O. S., Safwat, A. & Overgaard, J., 1993, In: Radiology and Oncology. 29, p. 51-59

**Is kidney the real dose-limiting organ after total body irradiation and bone marrow transplantation?**

Safwat, A. A., Nielsen, O. S. & Overgaard, J., 1993, In: European Journal of Cancer. 29A, 6, p. 929 1 p.

**Is kidney the real dose limiting organ after total body irradiation and bone marrow transplatation?**

Safwat, A., Nielsen, O. S. & Overgaard, J., 1993, In: European Journal of Cancer. 29A, 6, p. 921